Cabotegravir
-
Cabotegravir
structure -
-
CAS No:
1051375-10-0
-
Formula:
C19H17F2N3O5
-
Chemical Name:
Cabotegravir
-
Synonyms:
Oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide,N-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-,(3S,11aR)-;(3S,11aR)-N-[(2,4-Difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxooxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide;Cabotegravir;GSK 1265744A;GSK 744;(3s,11Ar)-n-(2,4-difluorobenzyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide;1229006-15-8;2316731-82-3
- Categories:
-
CAS No:
Description
Cabotegravir is a potent HIV integrase inhibitor as an oral lead-in tablet and long-acting injectable for the treatment and prevention of HIV infection. Cabotegravir is an inhibitor of OAT1 (IC50 0.81 μM) and OAT3 (IC50 0.41 μM).IC50 value: 0.81 μM (OAT1), 0.41 μM (OAT3) [1]Target: OAT1, OAT3Cabotegravir is a potent HIV integrase inhibitor in clinical development as an oral lead-in tablet and long-acting injectable for the treatment and prevention of HIV infection.[2] Cabotegravir is an
Cabotegravir is a monocarboxylic acid amide obtained by formal condensation of the carboxy group of (3S,11aR)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxylic acid with the amino group of 2,4-difluorobenzylamine. Used (as its sodium salt) for treatment of HIV-1. It has a role as a HIV-1 integrase inhibitor. It is a difluorobenzene, a secondary carboxamide, a monocarboxylic acid amide and an organic heterotricyclic compound. It is a conjugate acid of a cabotegravir(1-).|Cabotegravir has been investigated for the treatment of Acquired Immunodeficiency Syndrome.|Cabotegravir is a Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor. The mechanism of action of cabotegravir is as a HIV Integrase Inhibitor, and Organic Anion Transporter 1 Inhibitor, and Organic Anion Transporter 3 Inhibitor.
Cabotegravir Basic Attributes
405.3521864
405.35
HMH0132Z1Q
DTXSID50146982
J05AX|J - Antiinfectives for systemic use
Safety Information
|Warning|H400 (100%): Very toxic to aquatic life [Warning Hazardous to the aquatic environment, acute hazard]|P273, P391, and P501|The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.
Drug Information
Treatment of human immunodeficiency virus (HIV-1) infection|Vocabria tablets are indicated in combination with rilpivirine tablets for the short-term treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA
Inhibitors of HIV INTEGRASE, an enzyme required for integration of viral DNA into cellular DNA. (See all compounds classified as HIV Integrase Inhibitors.)
(3S,11aR)-N-((2,6-difluoropyridin-3-yl)methyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro(1,3)oxazolo(3,2-a)pyrido(1,2-d)pyrazine-8-carboxamide
Cabotegravir Use and Manufacturing
Human Drugs -> EU pediatric investigation plans|Human drugs -> Vocabria -> EMA Drug Category|Antivirals for systemic use -> Human pharmacotherapeutic group|Human Drugs -> FDA Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) -> Active Ingredients
Computed Properties
Molecular Weight:405.4
XLogP3:2.1
Hydrogen Bond Donor Count:2
Hydrogen Bond Acceptor Count:8
Rotatable Bond Count:3
Exact Mass:405.11362698
Monoisotopic Mass:405.11362698
Topological Polar Surface Area:99.2
Heavy Atom Count:29
Complexity:814
Defined Atom Stereocenter Count:2
Covalently-Bonded Unit Count:1
Compound Is Canonicalized:Yes
Recommended Suppliers of Cabotegravir
-
HK
2 YRS
Business licensedTrader Supplier of Weight Loss Peptide,Reta,Tirz,Sema,5 Amino 1mq,Cosmetic raw material,API,SLU-PP-332,Orforglipron,Pharmaceutical intermediates,Aniracetam,Paraxanthine,AF710B,Clascoterone,TAK-653,PRL-8-53InquiryCAS No.: 1051375-10-0Grade: Pharmaceutical GradeContent: 99% -
CN
5 YRS
Business licensedTrader Supplier of Intermediates,Building blocks,API,Silicones,Peptides,Lab chemicals,Biochemicals,Pharmaceuticals,Screening Compounds,Food Additives
Latest News on Cabotegravir
- BMS Over $900 Million to Help Develop Potential 'Best-in-class' SHP2 Inhibitors
- AbbVie's blockbuster product for atopic dermatitis, Upadacitinib, has been approved for marketing in the EU and Japan
- Designing peptide inhibitors for possible COVID-19 treatments
- Chinese scientists discover the inhibitors of SARS-CoV-2
Learn More Other Chemicals
-
Dabrafenib
1195765-45-7
-
BOC-VAL-VAL-OH
69209-73-0
-
BMS 303141
943962-47-8
-
(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylsulfanylbutanamide Formula
60117-17-1
-
(2S)-2-acetamido-6-amino-N-[(2S)-2-amino-3-methylbutanoyl]-N-propylhexanamide Formula
57899-96-4
-
1-(6-methoxy-1,3-benzothiazol-2-yl)-3-phenylurea Formula
26130-02-9
-
L-Tyrosyl-L-phenylalanine Structure
17355-11-2
-
C-REACTIVE PROTEIN FRAGMENT 77-82 Structure
130349-01-8
-
What is Sildenafil
139755-83-2
-
What is Dacomitinib
1110813-31-4